ATE546132T1 - Prozess zur veränderung der kristallform von mycophenolat natrium salz - Google Patents

Prozess zur veränderung der kristallform von mycophenolat natrium salz

Info

Publication number
ATE546132T1
ATE546132T1 AT04703158T AT04703158T ATE546132T1 AT E546132 T1 ATE546132 T1 AT E546132T1 AT 04703158 T AT04703158 T AT 04703158T AT 04703158 T AT04703158 T AT 04703158T AT E546132 T1 ATE546132 T1 AT E546132T1
Authority
AT
Austria
Prior art keywords
changing
sodium salt
crystal form
mycophenolate sodium
mycophenolate
Prior art date
Application number
AT04703158T
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546132(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE546132T1 publication Critical patent/ATE546132T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT04703158T 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz ATE546132T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
ATE546132T1 true ATE546132T1 (de) 2012-03-15

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04703158T ATE546132T1 (de) 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz

Country Status (32)

Country Link
US (3) US20060122265A1 (de)
EP (2) EP1592401B1 (de)
JP (1) JP4549976B2 (de)
KR (5) KR20090115821A (de)
CN (2) CN100595199C (de)
AR (2) AR043343A1 (de)
AT (1) ATE546132T1 (de)
AU (1) AU2004206731B2 (de)
BR (1) BRPI0406827A (de)
CA (2) CA2706900A1 (de)
CL (1) CL2004000073A1 (de)
CO (1) CO5580738A2 (de)
CY (1) CY1112772T1 (de)
DK (1) DK1592401T3 (de)
EC (1) ECSP055918A (de)
ES (1) ES2382035T3 (de)
GB (1) GB0301259D0 (de)
HK (1) HK1084874A1 (de)
IL (1) IL169484A (de)
MX (1) MXPA05007691A (de)
MY (1) MY148297A (de)
NO (1) NO20053846L (de)
NZ (1) NZ541073A (de)
PE (2) PE20040826A1 (de)
PL (2) PL213192B1 (de)
PT (1) PT1592401E (de)
RU (1) RU2388757C2 (de)
SG (1) SG155046A1 (de)
SI (1) SI1592401T1 (de)
TW (1) TWI325785B (de)
WO (1) WO2004064806A2 (de)
ZA (1) ZA200504442B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
WO2005105768A2 (en) 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1908756A1 (de) 2004-07-20 2008-04-09 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Herstellungsverfahren für kristallines Mycophenolat-Natrium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2011003731A (es) * 2008-10-09 2011-08-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Uso de solventes organicos en la granulacion humeda de moxifloxacino.
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
EP2488173A1 (de) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit verzögerter freisetzung
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
AR081036A1 (es) 2010-05-11 2012-05-30 Janssen Pharmaceutica Nv Formulaciones farmaceuticas para tratar enfermedades relacionadas con el transportador de glucosa dependiente de sodio
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
PT2697218T (pt) 2011-04-13 2016-07-13 Janssen Pharmaceutica Nv Processo para preparação de compostos úteis como inibidores da sglt2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
PL3394051T3 (pl) * 2015-12-21 2020-10-19 Janssen Pharmaceutica N.V. Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
DE69321531T2 (de) * 1992-08-04 1999-03-04 Toda Kogyo Corp Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
DK0724581T3 (da) 1993-09-15 1999-08-02 Syntex Inc Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20100120321A (ko) 2010-11-15
PT1592401E (pt) 2012-05-10
RU2005126328A (ru) 2006-07-27
KR20090115821A (ko) 2009-11-06
ECSP055918A (es) 2005-11-22
JP4549976B2 (ja) 2010-09-22
CY1112772T1 (el) 2016-02-10
HK1084874A1 (en) 2006-08-11
KR100855149B1 (ko) 2008-08-28
KR20090115898A (ko) 2009-11-09
PE20110276A1 (es) 2011-05-27
CN101333201A (zh) 2008-12-31
KR20070087181A (ko) 2007-08-27
KR101129105B1 (ko) 2012-04-12
IL169484A (en) 2016-03-31
EP2308471A1 (de) 2011-04-13
BRPI0406827A (pt) 2005-12-27
SG155046A1 (en) 2009-09-30
WO2004064806A2 (en) 2004-08-05
CN1738605A (zh) 2006-02-22
MY148297A (en) 2013-03-29
CA2706900A1 (en) 2004-08-05
PL393385A1 (pl) 2011-03-14
RU2388757C2 (ru) 2010-05-10
US8008511B2 (en) 2011-08-30
NO20053846L (no) 2005-08-16
DK1592401T3 (da) 2012-05-21
AU2004206731A8 (en) 2004-08-05
JP2006515016A (ja) 2006-05-18
ES2382035T3 (es) 2012-06-04
US20060122265A1 (en) 2006-06-08
CL2004000073A1 (es) 2005-01-14
PE20040826A1 (es) 2004-12-23
TWI325785B (en) 2010-06-11
GB0301259D0 (en) 2003-02-19
TW200505505A (en) 2005-02-16
ZA200504442B (en) 2006-02-22
KR20050096940A (ko) 2005-10-06
NZ541073A (en) 2008-12-24
CA2509796C (en) 2010-09-14
CA2509796A1 (en) 2004-08-05
PL376525A1 (pl) 2006-01-09
AR103711A2 (es) 2017-05-31
CN100595199C (zh) 2010-03-24
PL213192B1 (pl) 2013-01-31
WO2004064806A3 (en) 2004-10-28
US20090209639A1 (en) 2009-08-20
AU2004206731B2 (en) 2008-03-20
IL169484A0 (en) 2007-07-04
CO5580738A2 (es) 2005-11-30
US20110288313A1 (en) 2011-11-24
MXPA05007691A (es) 2005-09-30
EP1592401B1 (de) 2012-02-22
AR043343A1 (es) 2005-07-27
EP1592401A2 (de) 2005-11-09
SI1592401T1 (sl) 2012-05-31
AU2004206731A1 (en) 2004-08-05
US8124795B2 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
ATE546132T1 (de) Prozess zur veränderung der kristallform von mycophenolat natrium salz
DE602004026576D1 (de) Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60336326D1 (de) Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE602004026008D1 (de) Verfahren zur Herstellung von Flexodruckformen
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
DE602006004463D1 (de) Kristallform von asenapinmaleat
NO20041082L (no) Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
DE60209704D1 (de) Neue kristallforme von azithromycin
DE502005008502D1 (de) Vorrichtung zur veränderung der steuerzeiten von g
DE60234897D1 (de) Tintenzusatzmittel zur Verbesserung von Verzögerung der Tintentropfen
DE60330341D1 (de) Verfahren zur herstellung von wabenstrukturen
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
DE502004005616D1 (de) Keramisches filterelement zur reinigung von wasser
DE602004021052D1 (de) Herstellungsverfahren von Xylylendiamin
ATE286041T1 (de) Verfahren zur industriellen herstellung von 5- amino-3-carboxymethyl-4-cyano-2- thiphencarboxydimethylester
DE502004008678D1 (de) Verfahren zur Herstellung von gereinigten Elastomeren aus Lösung
DE60220554D1 (de) Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
FR2869030B1 (fr) Procede de production d'alpha-alumine particulaire
DE602004014217D1 (de) Verfahren für die Wiedergewinnung von Land Vorvertiefung
DE60312541D1 (de) Verfahren zur aufbereitung von sulfidmineralien
DE602004001646D1 (de) Verfahren zur Herstellung von Pyran
DE60232935D1 (de) Herstellungsverfahren von Druckeinheiten
DE50310774D1 (de) Verfahren zur Regelung des Fahrverhaltens zur Vermeidung des Untersteuerns
ATE332956T1 (de) Verfahren zur senkung der viskosität von weichspülern
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat